BioNexus Gene Lab (BGLC) Short-term Investments (2024 - 2026)

BioNexus Gene Lab's Short-term Investments history runs 3 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, down 40.72% from the prior year.
• Short-term Investments came in at $2.6 million for Q1 2026 at BioNexus Gene Lab, up from $1.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $2.8 million in Q4 2024 to a low of $1.7 million in Q4 2025.
• A 3-year average of $2.2 million and a median of $2.2 million in 2025 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 40.72% in 2025 and fell as far as 40.72% in 2025.
• BioNexus Gene Lab's Short-term Investments stood at $2.8 million in 2024, then plunged by 40.72% to $1.7 million in 2025, then surged by 58.63% to $2.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $2.6 million, $1.7 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison